Pasar al contenido principal

DESARROLLANDO UN TRATAMIENTO ACCESIBLE DE EDICION GENICA PARA ANEMIAS HEREDITARIAS

PID2023-152564OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO DE INVESTIGACION ENERGETICA MEDIOAMBIENTAL Y TECNOLOGICA (CIEMAT)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GPR41 and GPR43 modulate rodent pancreatic α-cell function and growth

  • Sánchez Roncero, Alicia
  • Fernández-Marcelo, Tamara
  • Pérez-Serra, Alexandra
  • Martínez-Oca, Paula
  • Alberquilla-Fernández, O.
  • Sánchez-Domínguez, R.
  • Segovia, José Carlos
  • Escrivá, Fernando
  • Galvez, Beatriz G.
  • Álvarez, Carmen P.
  • Marroqui, Laura
  • Fernández-Millán, Elisa
[Objective] While SCFA receptors GPR41 and GPR43 regulate β-cell insulin secretion, their role in α-cells remains unknown despite hyperglucagonemia in type 2 diabetes (T2D). Thus, the current study aims to investigate the ability of synthetic GPR41 and GPR43 agonists to modulate α-cell physiology and responsiveness to nutrient challenge., [Methods] Using αTC1.9 cells and primary rat islets we investigated the role of SCFA receptors in glucagon expression and secretion under physiological and insulin resistant conditions associated with high-fat feeding (HFD) and lactation (L). The specific agonists AR420626 (AR) and (S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl) butanamide (PA) were employed to study the mechanisms involved., [Results] Histological and flow cytometry analysis of islets demonstrated that GPR41 and GPR43 localized in α-cells. Treatment of αTC1.9 cells with the GPR41-agonist AR or GPR43-agonist PA increased Gcg expression and glucagon secretion at low glucose, while AR also potentiated glucagon release at high glucose. This effect was recapitulated in isolated islets demonstrating pertussis toxin sensitivity for both agonist effects. HFD-fed animals showed glucose intolerance, early fasting hyperglucagonemia and islet resistance to glucose inhibition of glucagon secretion together with enhanced expression of islet Gpr41/43. Stimulation of HFD islets with the synthetic agonists further increased Gcg expression. Pancreatic Gpr41/43 levels were also transiently induced during lactation although only GPR41 activation of lactating rat islets up-regulated Gcg expression via Gαi and α-cell replication., [Conclusions] These findings position GPR41 as a promising therapeutic target for modulating hyperglucagonemia and improving glycemic control in T2D, supporting its translational relevance in diabetes intervention strategies., This work was supported by the Ministerio de Ciencia, Innovación y Universidades [PID2020-116134RB-I00 (E.F-M.); PID2023-147823OB-I00 (L.M.); PID2023-152564OB-I00 (J.C.S.); CNS2022-135241 (B.G.G.); CNS2022-135505 (L.M.) funded by MICIN/AEI/10.13039/501100011033 and by NextGenerationEU/PRTR]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A presumed mouse parvovirus with overlooked high toxicity for human primitive CD34+ hematopoietic precursors in vitro and in bone marrow-humanized mice

  • Segovia, José C
  • Ramírez, Juan C
  • Río, Paula
  • Lotufo, Cecilia M
  • López-Bueno, Alberto
  • Calvo-López, Tania
  • Lamana, María L
  • Sandonís, Virginia
  • Balas, Antonio
  • Bautista-Santa Cruz, José M.
  • Abad, Paloma
  • Azcárate, Isabel G
  • Lopez Lorenzo, José L
  • Jalilian, Farid A L
  • Amini, Razieh
  • Kinnunen, Paula M
  • Jokelainen, Pikka
  • Mohanraj, Ushanandini
  • Söderlund-Venermo, Maria
  • Almendral, José M
Two strains of the minute virus of mice (MVM) parvovirus (of the species Protoparvovirus rodent1), named i (immunosuppressive) and p (prototype), show disparate tropism and pathogenicity in mice. Unlike the virulent MVMi, the MVMp is attenuated and infection-restricted in primary mouse hematopoietic cells; however, it does infect human transformed, established, and stem cells. We thus seek here a putative MVMp natural tropism to humans compared to MVMi. Infectious purified MVMp virions suppress in vitro the clonogenic potential of human committed (erythroid and myeloid) and primitive CD34+ progenitors, regardless of the cell source (umbilical cord blood, G-CSF mobilized peripheral blood, or bone marrow), in a multiplicity of infection-dependent manner. Furthermore, primitive CD34+ progenitors in culture are permissive to the MVMp cytotoxic NS-1 protein expression and the synthesis of viral genome replicative intermediates. None of these features is shared by MVMi. In consistency, MVMp suppresses the pool of CD34+ progenitors in bone-marrow-humanized immunodeficient NSG mice and severely compromises their survival, whereas in basal NSG mice, it replicates to several thousand-fold lower levels than MVMi and undergoes evolution to variants carrying genetic changes at the capsid tropism determinant binding sialic acid types. We suggest that MVMp may have originated from a MVMi-like mouse parvovirus upon adaptation to human sialic acid receptors in immunocompromised individuals. Extensive serological and genetic screens failed to demonstrate circulating MVMp in Eurasian and African human populations, including hematopoietic patients. Nevertheless, the high MVMp cytotoxicity to human primitive hematopoietic progenitors and rapid evolvability deserve further epidemiological studies. IMPORTANCE Assigning the genuine natural viral host range may be uncertain without testing the susceptibility of primary cells. Parvoviridae, a family of ssDNA icosahedral viruses, harbors several members infecting humans, but only parvovirus B19 of the Erythroparvovirus genus shows tropism for human hematopoietic progenitors. Here, we evaluate the tropism of the MVMi and MVMp parvoviruses for humans, which are assumed to be mouse pathogens. We show that MVMp is remarkably cytotoxic for human primitive CD34+ and committed erythroid and myeloid hematopoietic progenitors. Infection of basal and bone marrow-humanized immunodeficient mice shows the emergence of viral strain-specific genetic changes at the capsid domain binding sialic-acid receptors, denoting adaptation to the respective host hematopoiesis. Although a large epidemiological survey failed to identify circulating MVMp sequences or antibodies in human populations, its high toxicity to human hematopoietic progenitors of different lineages and primitiveness and rapid evolutionary capacity demand in-depth characterization of its potential pathogenicity for humans, FUNDING: Ministerio de Ciencia, Innovación y Universidades PID2023-152564OB-I00, PLEC2023-010243 (José C.Segovia) Ministerio de Ciencia, Innovación y Universidades PID2023-149637OB-I00 (José M. Bautista), Peer reviewed, Modelo experimental animal, Mamíferos - Roedores, in vitro - Tipos celulares - líneas celulares primarias